Jacques F Meis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11208321/publications.pdf

Version: 2024-02-01

14655 14208 19,357 218 66 128 citations h-index g-index papers 220 220 220 11362 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	South Asian (Clade I) <i>Candida auris</i> meningitis in a paediatric patient in Iran with a review of the literature. Mycoses, 2022, 65, 134-139.	4.0	20
2	A Chronic Autochthonous Fifth Clade Case of Candida auris Otomycosis in Iran. Mycopathologia, 2022, 187, 121-127.	3.1	18
3	Collateral consequences of agricultural fungicides on pathogenic yeasts: A One Health perspective to tackle azole resistance. Mycoses, 2022, 65, 303-311.	4.0	18
4	The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe, The, 2022, 3, e543-e552.	7.3	255
5	Molecular characterisation of <i>Candida auris</i> isolates from immunocompromised patients in a tertiaryâ€care hospital in Kuwait reveals a novel mutation in <i>FKS1</i> conferring reduced susceptibility to echinocandins. Mycoses, 2022, 65, 331-343.	4.0	25
6	Emergence of <i>Candida auris</i> in intensive care units in Algeria. Mycoses, 2022, 65, 753-759.	4.0	10
7	Global prevalence and subgroup analyses of coronavirus disease (<scp>COVID</scp> â€19) associated <i>Candida auris</i> infections (<scp>CACa</scp>): A systematic review and metaâ€analysis. Mycoses, 2022, 65, 683-703.	4.0	37
8	Activities of nine antifungal agents against Candida auris biofilms. Mycoses, 2021, 64, 381-384.	4.0	9
9	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infectious Diseases, The, 2021, 21, e149-e162.	9.1	586
10	COVID-19–Associated Pulmonary Aspergillosis, March–August 2020. Emerging Infectious Diseases, 2021, 27, 1077-1086.	4.3	175
11	Antifungal Activity of a Medical-Grade Honey Formulation against Candida auris. Journal of Fungi (Basel, Switzerland), 2021, 7, 50.	3.5	28
12	Colonisation and Transmission Dynamics of Candida auris among Chronic Respiratory Diseases Patients Hospitalised in a Chest Hospital, Delhi, India: A Comparative Analysis of Whole Genome Sequencing and Microsatellite Typing. Journal of Fungi (Basel, Switzerland), 2021, 7, 81.	3.5	29
13	COVIDâ€19–associated pulmonary aspergillosis: a prospective singleâ€center dual case series. Mycoses, 2021, 64, 457-464.	4.0	48
14	Genetic and Phenotypic Characterization of in-Host Developed Azole-Resistant Aspergillus flavus Isolates. Journal of Fungi (Basel, Switzerland), 2021, 7, 164.	3.5	3
15	Comparison of Two Commercially Available qPCR Kits for the Detection of Candida auris. Journal of Fungi (Basel, Switzerland), 2021, 7, 154.	3.5	12
16	Clade-specific chromosomal rearrangements and loss of subtelomeric adhesins in <i>Candida auris</i> . Genetics, 2021, 218, .	2.9	54
17	Are We Ready for Nosocomial Candida auris Infections? Rapid Identification and Antifungal Resistance Detection Using MALDI-TOF Mass Spectrometry May Be the Answer. Frontiers in Cellular and Infection Microbiology, 2021, 11, 645049.	3.9	6
18	Taxonomy of the Trichophyton mentagrophytes/T. interdigitale Species Complex Harboring the Highly Virulent, Multiresistant Genotype T. indotineae. Mycopathologia, 2021, 186, 315-326.	3.1	76

#	Article	IF	CITATIONS
19	Two Candida auris Cases in Germany with No Recent Contact to Foreign Healthcare—Epidemiological and Microbiological Investigations. Journal of Fungi (Basel, Switzerland), 2021, 7, 380.	3.5	6
20	Evaluation of DermaGenius < sup > ® < /sup > resistance realâ€time polymerase chain reaction for rapid detection of terbinafineâ€resistant <i>Trichophyton < /i> species. Mycoses, 2021, 64, 721-726.</i>	4.0	22
21	Axillary Digital Thermometers uplifted a multidrugâ€susceptible <i>Candidaauris</i> outbreak among COVIDâ€19 patients in Brazil. Mycoses, 2021, 64, 1062-1072.	4.0	40
22	Antifungal activity of nitroxoline against Candida auris isolates. Clinical Microbiology and Infection, 2021, 27, 1697.e7-1697.e10.	6.0	20
23	ECMM/ISHAM recommendations for clinical management of COVIDâ€19 associated mucormycosis in low― and middleâ€income countries. Mycoses, 2021, 64, 1028-1037.	4.0	137
24	Antifungal Susceptibility and Mutations in the Squalene Epoxidase Gene in Dermatophytes of the Trichophyton mentagrophytes Species Complex. Antimicrobial Agents and Chemotherapy, 2021, 65, e0005621.	3.2	49
25	Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infectious Diseases, The. 2021. 21. e246-e257.	9.1	167
26	Diagnostic Allele-Specific PCR for the Identification of Candida auris Clades. Journal of Fungi (Basel,) Tj ETQq0 0	0 rgBT /O\	verlgck 10 Tf 5
27	<i>In vitro</i> activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including <i>Penicillium</i> and <i>Talaromyces</i> species. Journal of Antimicrobial Chemotherapy, 2021, 76, 1229-1233.	3.0	23
28	Multi-locus sequence typing reveals genotypic similarity in Nigerian Cryptococcus neoformans AFLP1/VNI of environmental and clinical origin. Journal of Medical Microbiology, 2021, 70, .	1.8	2
29	<i>In vitro</i> activity of eight antifungal drugs against <i>Chaetomiaceae</i> . Medical Mycology, 2021, 60, .	0.7	1
30	Candida auris—"Ten Years After― Journal of Fungi (Basel, Switzerland), 2020, 6, 2.	3.5	4
31	In vitro characterization, ADME analysis, and histological and toxicological evaluation of BM1, a macrocyclic amidinourea active against azole-resistant Candida strains. International Journal of Antimicrobial Agents, 2020, 55, 105865.	2.5	15
32	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020, 71, 1367-1376.	5.8	1,429
33	A Cluster of Candida auris Blood Stream Infections in a Tertiary Care Hospital in Oman from 2016 to 2019. Antibiotics, 2020, 9, 638.	3.7	24
34	Clonal Expansion of Environmental Triazole Resistant Aspergillus fumigatus in Iran. Journal of Fungi (Basel, Switzerland), 2020, 6, 199.	3.5	16
35	A Multidisciplinary Approach to Fungal Infections: One-Year Experiences of a Center of Expertise in Mycology. Journal of Fungi (Basel, Switzerland), 2020, 6, 274.	3.5	7
36	Molecular Epidemiology of Candida Auris Outbreak in a Major Secondary-Care Hospital in Kuwait. Journal of Fungi (Basel, Switzerland), 2020, 6, 307.	3 . 5	33

#	Article	IF	CITATIONS
37	No to <i>Neocosmospora</i> : Phylogenomic and Practical Reasons for Continued Inclusion of the Fusarium solani Species Complex in the Genus <i>Fusarium</i> . MSphere, 2020, 5, .	2.9	61
38	Evaluation of Microsatellite Typing, ITS Sequencing, AFLP Fingerprinting, MALDI-TOF MS, and Fourier-Transform Infrared Spectroscopy Analysis of Candida auris. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgBT /C	Ovedack 10	0 T 25 0 697 Td
39	Transcriptional and functional insights into the host immune response against the emerging fungal pathogen Candida auris. Nature Microbiology, 2020, 5, 1516-1531.	13.3	7 5
40	Development of Candida auris Short Tandem Repeat Typing and Its Application to a Global Collection of Isolates. MBio, 2020, 11 , .	4.1	56
41	Azole-Resistant COVID-19-Associated Pulmonary Aspergillosis in an Immunocompetent Host: A Case Report. Journal of Fungi (Basel, Switzerland), 2020, 6, 79.	3.5	88
42	Paradoxal Trends in Azole-Resistant <i>Aspergillus fumigatus</i> in a National Multicenter Surveillance Program, the Netherlands, 2013–2018. Emerging Infectious Diseases, 2020, 26, 1447-1455.	4.3	46
43	European confederation of medical mycology expert consult—An ECMM excellence center initiative. Mycoses, 2020, 63, 566-572.	4.0	8
44	Outbreak of <i>Dirkmeia churashimaensis</i> Fungemia in a Neonatal Intensive Care Unit, India. Emerging Infectious Diseases, 2020, 26, 764-768.	4.3	7
45	Antifungal Activity of a Novel Triazole, Efinaconazole and Nine Comparators against 354 Molecularly Identified Aspergillus Isolates. Mycopathologia, 2020, 185, 357-365.	3.1	6
46	International Society for Human and Animal Mycology (ISHAM)—New Initiatives. Journal of Fungi (Basel, Switzerland), 2020, 6, 97.	3.5	4
47	First azoleâ€resistant <i>Aspergillus fumigatus</i> isolates with the environmental TR ₄₆ /Y121F/T289A mutation in Iran. Mycoses, 2020, 63, 430-436.	4.0	29
48	Antifungal resistance in clinically significant fungi. Fungal Genetics and Biology, 2020, 139, 103369.	2.1	1
49	Prevalence and Clonal Distribution of Azole-Resistant Candida parapsilosis Isolates Causing Bloodstream Infections in a Large Italian Hospital. Frontiers in Cellular and Infection Microbiology, 2020, 10, 232.	3.9	48
50	High-Frequency Direct Detection of Triazole Resistance in Aspergillus fumigatus from Patients with Chronic Pulmonary Fungal Diseases in India. Journal of Fungi (Basel, Switzerland), 2020, 6, 67.	3.5	30
51	In Vitro Interaction of Geldanamycin with Triazoles and Echinocandins Against Common and Emerging Candida Species. Mycopathologia, 2019, 184, 607-613.	3.1	24
52	Potential Fifth Clade of <i>Candida auris, </i> Iran, 2018. Emerging Infectious Diseases, 2019, 25, 1780-1781.	4.3	257
53	Anti-fungal activity of a novel triazole, PC1244, against emerging azole-resistant Aspergillus fumigatus and other species of Aspergillus. Journal of Antimicrobial Chemotherapy, 2019, 74, 2950-2958.	3.0	12
54	Invasive Aspergillosis by Aspergillus flavus: Epidemiology, Diagnosis, Antifungal Resistance, and Management. Journal of Fungi (Basel, Switzerland), 2019, 5, 55.	3.5	149

#	Article	IF	Citations
55	ECMM <i>Candi</i> Regâ€"A ready to use platform for outbreaks and epidemiological studies. Mycoses, 2019, 62, 920-927.	4.0	19
56	External Quality Assessment Evaluating the Ability of Dutch Clinical Microbiological Laboratories to Identify Candida auris. Journal of Fungi (Basel, Switzerland), 2019, 5, 94.	3 . 5	11
57	Thermogenic Characterization and Antifungal Susceptibility of Candida auris by Microcalorimetry. Journal of Fungi (Basel, Switzerland), 2019, 5, 103.	3.5	8
58	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infectious Diseases, The, 2019, 19, e405-e421.	9.1	970
59	A novel diagnosis scoring model to predict invasive pulmonary aspergillosis in the intensive care unit. Journal of King Abdulaziz University, Islamic Economics, 2019, 40, 140-146.	1.1	7
60	Ongoing Challenges with Healthcare-Associated Candida auris Outbreaks in Oman. Journal of Fungi (Basel, Switzerland), 2019, 5, 101.	3 . 5	34
61	<i>cyp51A</i> Mutations, Extrolite Profiles, and Antifungal Susceptibility in Clinical and Environmental Isolates of the Aspergillus viridinutans Species Complex. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	17
62	A unique multidrug-resistant clonal Trichophyton population distinct from Trichophyton mentagrophytes/Trichophyton interdigitale complex causing an ongoing alarming dermatophytosis outbreak in India: Genomic insights and resistance profile. Fungal Genetics and Biology, 2019, 133, 103266.	2.1	93
63	The First Two Cases of CandidaÂauris in The Netherlands. Journal of Fungi (Basel, Switzerland), 2019, 5, 91.	3.5	18
64	Candida auris Identification and Rapid Antifungal Susceptibility Testing Against Echinocandins by MALDI-TOF MS. Frontiers in Cellular and Infection Microbiology, 2019, 9, 20.	3.9	48
65	A simple and low cost tetra-primer ARMS-PCR method for detection triazole-resistant Aspergillus fumigatus. Molecular Biology Reports, 2019, 46, 4537-4543.	2.3	7
66	Does Online Search Behavior Coincide with Candida auris Cases? An Exploratory Study. Journal of Fungi (Basel, Switzerland), 2019, 5, 44.	3.5	3
67	Brazil is so far free from Candida auris. Are we missing something?. Brazilian Journal of Infectious Diseases, 2019, 23, 149-150.	0.6	2
68	Effects of the Natural Peptide Crotamine from a South American Rattlesnake on Candida auris, an Emergent Multidrug Antifungal Resistant Human Pathogen. Biomolecules, 2019, 9, 205.	4.0	31
69	Nonrandom Distribution of Azole Resistance across the Global Population of Aspergillus fumigatus. MBio, 2019, 10, .	4.1	71
70	Fungicide-driven alterations in azole-resistant <i>Aspergillus fumigatus</i> are related to vegetable crops in Colombia, South America. Mycologia, 2019, 111, 217-224.	1.9	34
71	Molecular Characterization and Antifungal Susceptibility of Clinical Fusarium Species From Brazil. Frontiers in Microbiology, 2019, 10, 737.	3 . 5	49
72	Emergence of clonal fluconazole-resistant Candida parapsilosis clinical isolates in a multicentre laboratory-based surveillance study in India. Journal of Antimicrobial Chemotherapy, 2019, 74, 1260-1268.	3.0	61

#	Article	IF	CITATIONS
73	Killing of <i>Candida auris</i> by <scp>UV</scp> â€C: Importance of exposure time and distance. Mycoses, 2019, 62, 408-412.	4.0	49
74	<p>Multiresistant Fusarium Pathogens on Plants and Humans: Solutions in (from) the Antifungal Pipeline?</p> . Infection and Drug Resistance, 2019, Volume 12, 3727-3737.	2.7	24
75	<i>Candida auris</i> otomycosis in Iran and review of recent literature. Mycoses, 2019, 62, 101-105.	4.0	75
76	Perspectives on misidentification of <i>Trichophyton interdigitale</i> Italian interdigitaleItalian interdigitaleItalian interdigitaleItalian interdigitaleItalian interdigitaleItalian interdigitaleItalian interdigitaleItalian interdigitale Perspectives on misidentification of <i>Italian Italian Interdigitale Italian</i>	4.0	40
77	Prevalence and diversity of filamentous fungi in the airways of cystic fibrosis patients – A Dutch, multicentre study. Journal of Cystic Fibrosis, 2019, 18, 221-226.	0.7	55
78	Indifferent effect of nonsteroidal anti-inflammatory drugs (NSAIDs) combined with fluconazole against multidrug-resistant Candida auris. Current Medical Mycology, 2019, 5, 26-30.	0.8	6
79	Comparative virulence of <i>Candida auris</i> with <i>Candida haemulonii</i> , <i> Candida glabrata</i> and <i>Candida albicans</i> in a murine model. Mycoses, 2018, 61, 377-382.	4.0	98
80	Fusarium metavorans sp. nov.: The frequent opportunist  FSSC6'. Medical Mycology, 2018, 56, S144-S152.	0.7	15
81	Postâ€influenzal triazoleâ€resistant aspergillosis following allogeneic stem cell transplantation. Mycoses, 2018, 61, 570-575.	4.0	15
82	High terbinafine resistance in <i>Trichophyton interdigitale</i> isolates in Delhi, India harbouring mutations in the squalene epoxidase gene. Mycoses, 2018, 61, 477-484.	4.0	237
83	An outbreak due to <i>Candida auris</i> with prolonged colonisation and candidaemia in a tertiary care European hospital. Mycoses, 2018, 61, 498-505.	4.0	236
84	Pharmacodynamics of Voriconazole for Invasive Pulmonary Scedosporiosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	5
85	Emergence of azole resistant <i>Aspergillus fumigatus</i> and One Health: time to implement environmental stewardship. Environmental Microbiology, 2018, 20, 1299-1301.	3.8	47
86	Breakthrough candidemia after the introduction of broad spectrum antifungal agents: A 5-year retrospective study. Medical Mycology, 2018, 56, 406-415.	0.7	20
87	Development of Echinocandin Resistance in Candida tropicalis following Short-Term Exposure to Caspofungin for Empiric Therapy. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	32
88	Identification of uncommon oral yeasts from cancer patients by MALDI-TOF mass spectrometry. BMC Infectious Diseases, 2018, 18, 24.	2.9	86
89	Differential In Vitro Cytokine Induction by the Species of Cryptococcus gattii Complex. Infection and Immunity, 2018, 86, .	2.2	7
90	A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009–17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. Journal of Antimicrobial Chemotherapy, 2018, 73, 891-899.	3.0	380

#	Article	IF	Citations
91	EQUAL Candida Score: An <scp>ECMM</scp> score derived from current guidelines to measure QUAlity of Clinical Candidaemia Management. Mycoses, 2018, 61, 326-330.	4.0	60
92	Candida infanticola and Candida spencermartinsiae yeasts: Possible emerging species in cancer patients. Microbial Pathogenesis, 2018, 115, 353-357.	2.9	9
93	Airway persistence by the emerging multiâ€azoleâ€resistant <i>Rasamsonia argillacea</i> complex in cystic fibrosis. Mycoses, 2018, 61, 665-673.	4.0	13
94	In vitro combination of voriconazole with micafungin against azole-resistant clinical isolates of Aspergillus fumigatus from different geographical regions. Diagnostic Microbiology and Infectious Disease, 2018, 91, 266-268.	1.8	8
95	Triazole resistance surveillance in Aspergillus fumigatus. Medical Mycology, 2018, 56, S83-S92.	0.7	114
96	Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	27
97	Current antifungal treatment of fusariosis. International Journal of Antimicrobial Agents, 2018, 51, 326-332.	2.5	83
98	Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs. Journal of Antimicrobial Chemotherapy, 2018, 73, 134-142.	3.0	29
99	Use of cell surface protein typing for genotyping of azoleâ€resistant and â€susceptible <i>Aspergillus fumigatus</i> isolates in Iran. Mycoses, 2018, 61, 143-147.	4.0	8
100	In vitro antifungal activity of amphotericin B and 11 comparators against <i>Aspergillus terreus</i> species complex. Mycoses, 2018, 61, 134-142.	4.0	29
101	The world's ten most feared fungi. Fungal Diversity, 2018, 93, 161-194.	12.3	85
102	Antifungal Resistance: Specific Focus on Multidrug Resistance in Candida auris and Secondary Azole Resistance in Aspergillus fumigatus. Journal of Fungi (Basel, Switzerland), 2018, 4, 129.	3.5	29
103	Candida auris: a global fungal public health threat. Lancet Infectious Diseases, The, 2018, 18, 1298-1299.	9.1	69
104	Comparative genotyping and phenotyping of Aspergillus fumigatus isolates from humans, dogs and the environment. BMC Microbiology, 2018, 18, 118.	3.3	14
105	Low <i>In Vitro</i> Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	18
106	Itraconazole, Voriconazole, and Posaconazole CLSI MIC Distributions for Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates. Journal of Fungi (Basel, Switzerland), 2018, 4, 103.	3.5	38
107	Mycotic Keratitis Caused by Fusarium solani sensu stricto (FSSC5): A Case Series. Mycopathologia, 2018, 183, 835-840.	3.1	9
108	Internal validation of <scp>GPS</scp> ^{â,,¢} <scp>MONODOSE</scp> CanAur dtecâ€ <scp>qPCR</scp> kit following the <scp>UNE</scp> / <scp>EN ISO</scp> /cscp>IEC 17025:2005 for detection of the emerging yeast <i>Candida auris</i> . Mycoses, 2018, 61, 877-884.	4.0	28

#	Article	IF	Citations
109	Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: New leadership is about working together. Mycoses, 2018, 61, 885-894.	4.0	52
110	Candida auris. Current Opinion in Infectious Diseases, 2018, 31, 334-340.	3.1	62
111	Molecular characterization and antifungal susceptibility testing of Cryptococcus neoformans sensu stricto from southern Brazil. Journal of Medical Microbiology, 2018, 67, 560-569.	1.8	15
112	Global Population Genetic Analysis of Aspergillus fumigatus. MSphere, 2017, 2, .	2.9	71
113	Intercountry Transfer of Triazole-Resistant Aspergillus fumigatus on Plant Bulbs. Clinical Infectious Diseases, 2017, 65, 147-149.	5.8	63
114	Changes in In Vitro Susceptibility Patterns of Aspergillus to Triazoles and Correlation With Aspergillosis Outcome in a Tertiary Care Cancer Center, 1999–2015. Clinical Infectious Diseases, 2017, 65, 216-225.	5.8	50
115	Azole-resistant Aspergillus fumigatus harboring TR34/L98H, TR46/Y121F/T289A and TR53 mutations related to flower fields in Colombia. Scientific Reports, 2017, 7, 45631.	3.3	96
116	<i>Fusarium</i> species causing eumycetoma: Report of two cases and comprehensive review of the literature. Mycoses, 2017, 60, 204-212.	4.0	26
117	Azole-Resistant Aspergillosis: Epidemiology, Molecular Mechanisms, and Treatment. Journal of Infectious Diseases, 2017, 216, S436-S444.	4.0	199
118	<i>In Vitro</i> Interactions of Echinocandins with Triazoles against Multidrug-Resistant <i>Candida auris</i> . Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	75
119	Triazole Resistance Is Still Not Emerging in Aspergillus fumigatus Isolates Causing Invasive Aspergillosis in Brazilian Patients. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	7
120	Importance of Resolving Fungal Nomenclature: the Case of Multiple Pathogenic Species in the <i>Cryptococcus</i> Genus. MSphere, 2017, 2, .	2.9	124
121	The first cases of <i>Candida auris</i> candidaemia in Oman. Mycoses, 2017, 60, 569-575.	4.0	66
122	A Novel Environmental Azole Resistance Mutation in Aspergillus fumigatus and a Possible Role of Sexual Reproduction in Its Emergence. MBio, 2017, 8, .	4.1	104
123	Pharmacodynamics of Voriconazole against Wild-Type and Azole-Resistant Aspergillus flavus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	18
124	Simultaneous Emergence of Multidrug-Resistant <i>Candida auris</i> on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. Clinical Infectious Diseases, 2017, 64, 134-140.	5.8	1,099
125	Comparative Evaluation of Etest, EUCAST, and CLSI Methods for Amphotericin B, Voriconazole, and Posaconazole against Clinically Relevant Fusarium Species. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	21
126	Home Environment as a Source of Life-Threatening Azole-Resistant <i>Aspergillus fumigatus</i> Immunocompromised Patients: Table 1 Clinical Infectious Diseases, 2017, 64, 76-78.	5.8	48

#	Article	IF	CITATIONS
127	Ecoepidemiology of Cryptococcus gattii in Developing Countries. Journal of Fungi (Basel,) Tj ETQq1 1 0.784314 r	gBT/Overl	ogk 10 Tf 50
128	Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathogens, 2017, 13, e1006290.	4.7	501
129	Outbreak of Fusarium oxysporum infections in children with cancer: an experience with 7 episodes of catheter-related fungemia. Antimicrobial Resistance and Infection Control, 2017, 6, 93.	4.1	26
130	Antifungal Susceptibility Testing of Fusarium: A Practical Approach. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgBT /O	verlock 10 3.5	Tf 50 622 To
131	Fusarium: Molecular Diversity and Intrinsic Drug Resistance. PLoS Pathogens, 2016, 12, e1005464.	4.7	314
132	Filamentous Fungi in Respiratory Infections. What Lies Beyond Aspergillosis and Mucormycosis?. PLoS Pathogens, 2016, 12, e1005491.	4.7	46
133	Diagnosis and management of aspergillosis in the Netherlands: a national survey. Mycoses, 2016, 59, 101-107.	4.0	36
134	Comparison of biotyping methods as alternative identification tools to molecular typing of pathogenic <i><scp>C</scp>ryptococcus</i> species in subâ€Saharan Africa. Mycoses, 2016, 59, 151-156.	4.0	9
135	Epidemiology and molecular mechanisms of antifungal resistance in \hat{A} (i> Candida < /i> and <i> Aspergillus < /i> . Mycoses, 2016, 59, 198-219.</i>	4.0	142
136	Identification and typing of the emerging pathogen <i>Candida auris</i> by matrixâ€essisted laser desorption ionisation time of flight mass spectrometry. Mycoses, 2016, 59, 535-538.	4.0	86
137	First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrobial Resistance and Infection Control, 2016, 5, 35.	4.1	535
138	Global molecular epidemiology and genetic diversity of $\langle i \rangle$ Fusarium $\langle i \rangle$, a significant emerging group of human opportunists from 1958 to 2015. Emerging Microbes and Infections, 2016, 5, 1-11.	6.5	89
139	Clinical implications of globally emerging azole resistance in <i>Aspergillus fumigatus</i> Philosophical Transactions of the Royal Society B: Biological Sciences, 2016, 371, 20150460.	4.0	243
140	Cryptococcus tetragattii as a major cause of cryptococcal meningitis among HIV-infected individuals in Harare, Zimbabwe. Journal of Infection, 2016, 72, 745-752.	3.3	31
141	<i>Candida haemulonii</i> species complex: an emerging species in India and its genetic diversity assessed with multilocus sequence and amplified fragment-length polymorphism analyses. Emerging Microbes and Infections, 2016, 5, 1-12.	6.5	55
142	Are the TR ₄₆ /Y121F/T289A Mutations in Azole-Resistant Aspergillosis Patient Acquired or Environmental?. Antimicrobial Agents and Chemotherapy, 2016, 60, 3259-3260.	3.2	12
143	In vitro antifungal susceptibility profiles of Cryptococcus species isolated from HIV-associated cryptococcal meningitis patients in Zimbabwe. Diagnostic Microbiology and Infectious Disease, 2016, 86, 289-292.	1.8	12
144	First report of Candida auris in America: Clinical and microbiological aspects of 18 episodes of candidemia. Journal of Infection, 2016, 73, 369-374.	3.3	340

#	Article	IF	CITATIONS
145	Potent Activities of Novel Imidazoles Lanoconazole and Luliconazole against a Collection of Azole-Resistant and -Susceptible Aspergillus fumigatus Strains. Antimicrobial Agents and Chemotherapy, 2016, 60, 6916-6919.	3.2	39
146	Azole resistance surveillance in <i>Aspergillus fumigatus</i> : beneficial or biased?. Journal of Antimicrobial Chemotherapy, 2016, 71, 2079-2082.	3.0	49
147	In-host adaptation and acquired triazole resistance in Aspergillus fumigatus: a dilemma for clinical management. Lancet Infectious Diseases, The, 2016, 16, e251-e260.	9.1	123
148	Molecular epidemiology and <i>in vitro</i> antifungal susceptibility testing of 108 clinical <i>Cryptococcus neoformans sensu lato</i> and <i>Cryptococcus gattii sensu lato</i> isolates from Denmark. Mycoses, 2016, 59, 576-584.	4.0	46
149	Discovery of a sexual cycle in <i>Talaromyces amestolkiae</i> . Mycologia, 2016, 108, 70-79.	1.9	8
150	<i>In vitro</i> combinations of natamycin with voriconazole, itraconazole and micafungin against clinical <i>Fusarium</i> strains causing keratitis: TableÂ1 Journal of Antimicrobial Chemotherapy, 2016, 71, 953-955.	3.0	53
151	Bipolaris oryzae, a novel fungal opportunist causing keratitis. Diagnostic Microbiology and Infectious Disease, 2016, 85, 61-65.	1.8	7
152	Azole Resistance in <i>Aspergillus fumigatus</i> : Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?. Clinical Infectious Diseases, 2016, 62, 362-368.	5 . 8	468
153	DNA barcoding, MALDI-TOF, and AFLP data support Fusarium ficicrescens as a distinct species within the Fusarium fujikuroi species complex. Fungal Biology, 2016, 120, 265-278.	2.5	40
154	Non-traumatic keratitis due to Colletotrichum truncatum. JMM Case Reports, 2016, 3, e005047.	1.3	4
155	Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex. Journal of Antimicrobial Chemotherapy, 2015, 70, 1068-71.	3.0	81
156	Cryptococcal meningitis due to <i>Cryptococcus neoformans</i> genotype <scp>AFLP</scp> 1/ <scp> VNI</scp> in Iran: a review of the literature. Mycoses, 2015, 58, 689-693.	4.0	16
157	Prevalence and mechanism of triazole resistance in Aspergillus fumigatus in a referral chest hospital in Delhi, India and an update of the situation in Asia. Frontiers in Microbiology, 2015, 06, 428.	3.5	89
158	Molecular Epidemiology and In-Vitro Antifungal Susceptibility of Aspergillus terreus Species Complex Isolates in Delhi, India: Evidence of Genetic Diversity by Amplified Fragment Length Polymorphism and Microsatellite Typing. PLoS ONE, 2015, 10, e0118997.	2.5	53
159	First Description of Azole-Resistant Aspergillus fumigatus Due to TR ₄₆ /Y121F/T289A Mutation in France. Antimicrobial Agents and Chemotherapy, 2015, 59, 4331-4335.	3.2	61
160	Comparison of the EUCAST and CLSI Broth Microdilution Methods for Testing Isavuconazole, Posaconazole, and Amphotericin B against Molecularly Identified Mucorales Species. Antimicrobial Agents and Chemotherapy, 2015, 59, 7882-7887.	3.2	41
161	Triazole-resistant Aspergillus fumigatus harbouring G54 mutation: Is it de novo or environmentally acquired?. Journal of Global Antimicrobial Resistance, 2015, 3, 69-74.	2.2	81
162	Pharmacodynamics of Isavuconazole in an Aspergillus fumigatus Mouse Infection Model. Antimicrobial Agents and Chemotherapy, 2015, 59, 2855-2866.	3.2	60

#	Article	IF	Citations
163	Multidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek 2, CLSI Broth Microdilution, and Etest Method. Journal of Clinical Microbiology, 2015, 53, 1823-1830.	3.9	409
164	Draft Genome Sequence of a Fluconazole-Resistant <i>Candida auris </i> Strain from a Candidemia Patient in India. Genome Announcements, 2015, 3, .	0.8	62
165	Genomic Context of Azole Resistance Mutations in Aspergillus fumigatus Determined Using Whole-Genome Sequencing. MBio, 2015, 6, e00536.	4.1	171
166	<i>In vitro</i> susceptibility patterns of clinically important <i>Trichophyton</i> and <i>Epidermophyton</i> species against nine antifungal drugs. Mycoses, 2015, 58, 303-307.	4.0	64
167	Multiâ€triazoleâ€resistant <i>Aspergillus fumigatus</i> infections in Australia. Mycoses, 2015, 58, 350-355.	4.0	89
168	Candida parapsilosis Resistance to Fluconazole: Molecular Mechanisms and <i>In Vivo</i> Impact in Infected Galleria mellonella Larvae. Antimicrobial Agents and Chemotherapy, 2015, 59, 6581-6587.	3.2	106
169	International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resistance Updates, 2015, 21-22, 30-40.	14.4	262
170	Concomitant occurrence of itraconazole-resistant and -susceptible strains of Aspergillus fumigatus in routine cultures. Journal of Antimicrobial Chemotherapy, 2015, 70, 412-415.	3.0	55
171	Commentaries: Name Changes in Medically Important Fungi and Their Implications for Clinical Practice. Journal of Clinical Microbiology, 2015, 53, 1056-1062.	3.9	65
172	Cryptococcus gattii genotype AFLP6/VGII meningoencephalitis in an immunocompetent Filipino male in Kuwait: activation of a dormant infection. JMM Case Reports, 2015, 2, .	1.3	3
173	Cryptococcus and Cryptococcosis in Cuba. A minireview. Mycoses, 2014, 57, 707-717.	4.0	15
174	Voriconazole-Resistant Penicillium oxalicum: An Emerging Pathogen in Immunocompromised Hosts. Open Forum Infectious Diseases, 2014, 1, ofu029.	0.9	23
175	Passive Surveillance for Azole-Resistant <i>Aspergillus fumigatus</i> , United States, 2011–2013. Emerging Infectious Diseases, 2014, 20, 1498-1503.	4.3	76
176	Multi-azole-resistant Aspergillus fumigatus in the environment in Tanzania. Journal of Antimicrobial Chemotherapy, 2014, 69, 2979-2983.	3.0	122
177	Recognizing filamentous basidiomycetes as agents of human disease: A review. Medical Mycology, 2014, 52, 782-797.	0.7	76
178	Molecular characterization and <i>in vitro</i> antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India. Mycoses, 2014, 57, 97-107.	4.0	48
179	Proposed nomenclature for Pseudallescheria, Scedosporium and related genera. Fungal Diversity, 2014, 67, 1-10.	12.3	152
180	Azole-resistant Aspergillus fumigatus with the environmental TR46/Y121F/T289A mutation in India. Journal of Antimicrobial Chemotherapy, 2014, 69, 555-557.	3.0	113

#	Article	IF	CITATIONS
181	Molecular epidemiology and antifungal susceptibility of Serbian <i>Cryptococcus neoformans</i> isolates. Mycoses, 2014, 57, 380-387.	4.0	33
182	Exploring azole antifungal drug resistance in <i>Aspergillus fumigatus</i> with special reference to resistance mechanisms. Future Microbiology, 2014, 9, 697-711.	2.0	118
183	Molecular characterization of Cryptococcus gattii genotype AFLP6/VGII isolated from woody debris of divi-divi (Caesalpinia coriaria), Bonaire, Dutch Caribbean. Revista Iberoamericana De Micologia, 2014, 31, 193-196.	0.9	12
184	Simple, Low-Cost Molecular Assays for TR34/L98H Mutations in the cyp51A Gene for Rapid Detection of Triazole-Resistant Aspergillus fumigatus Isolates. Journal of Clinical Microbiology, 2014, 52, 2223-2227.	3.9	20
185	Occurrence of triazole-resistant Aspergillus fumigatus with TR34/L98H mutations in outdoor and hospital environment in Kuwait. Environmental Research, 2014, 133, 20-26.	7.5	64
186	Allergic bronchopulmonary mycosis due to fungi other than <i>Aspergillus</i> : a global overview. Critical Reviews in Microbiology, 2014, 40, 30-48.	6.1	174
187	Fatal Cryptococcus gattii genotype AFLP5 infection in an immunocompetent Cuban patient. Medical Mycology Case Reports, 2013, 2, 48-51.	1.3	15
188	New Clonal Strain of <i>Candida auris </i> , Delhi, India. Emerging Infectious Diseases, 2013, 19, 1670-1673.	4.3	320
189	Emergence of Azole-Resistant Aspergillus fumigatus Strains due to Agricultural Azole Use Creates an Increasing Threat to Human Health. PLoS Pathogens, 2013, 9, e1003633.	4.7	300
190	Clinical Significance of Filamentous Basidiomycetes Illustrated by Isolates of the Novel Opportunist Ceriporia lacerata from the Human Respiratory Tract. Journal of Clinical Microbiology, 2013, 51, 585-590.	3.9	37
191	Clinical Significance and Molecular Characterization of Nonsporulating Molds Isolated from the Respiratory Tracts of Bronchopulmonary Mycosis Patients with Special Reference to Basidiomycetes. Journal of Clinical Microbiology, 2013, 51, 3331-3337.	3.9	60
192	Molecular Characterization and <i>In Vitro</i> Antifungal Susceptibility Profile of Schizophyllum commune, an Emerging Basidiomycete in Bronchopulmonary Mycoses. Antimicrobial Agents and Chemotherapy, 2013, 57, 2845-2848.	3.2	35
193	Reply to "Implications of High Antifungal Susceptibility on Schizophyllum commune-Associated Allergy in Clinical Practice― Antimicrobial Agents and Chemotherapy, 2013, 57, 5784-5785.	3.2	3
194	Environmental study of azoleâ€resistant <i><scp>A</scp>spergillus fumigatus</i> with TR ₃₄ /L98H mutations in the <i>cyp51</i> A gene in <scp>I</scp> ran. Mycoses, 2013, 56, 659-663.	4.0	98
195	Microcalorimetry Assay for Rapid Detection of Voriconazole Resistance in Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2013, 57, 5704-5706.	3.2	7
196	Ancient Dispersal of the Human Fungal Pathogen Cryptococcus gattii from the Amazon Rainforest. PLoS ONE, 2013, 8, e71148.	2.5	122
197	Geographically Structured Populations of Cryptococcus neoformans Variety grubii in Asia Correlate with HIV Status and Show a Clonal Population Structure. PLoS ONE, 2013, 8, e72222.	2.5	83
198	Meningitis caused by <i>Filobasidium uniguttulatum</i> : case report and overview of the literature. Mycoses, 2012, 55, 105-109.	4.0	22

#	Article	IF	Citations
199	Autochthonous and Dormant <i>Cryptococcus gattii</i> li>Infections in Europe. Emerging Infectious Diseases, 2012, 18, 1618-1624.	4.3	132
200	Species-Specific Antifungal Susceptibility Patterns of Scedosporium and Pseudallescheria Species. Antimicrobial Agents and Chemotherapy, 2012, 56, 2635-2642.	3.2	244
201	Extensive Genetic Diversity within the Dutch Clinical Cryptococcus neoformans Population. Journal of Clinical Microbiology, 2012, 50, 1918-1926.	3.9	53
202	Molecular Epidemiology of Aspergillus fumigatus Isolates Harboring the TR ₃₄ /L98H Azole Resistance Mechanism. Journal of Clinical Microbiology, 2012, 50, 2674-2680.	3.9	127
203	Antifungal Susceptibility and Phylogeny of Opportunistic Members of the Order Mucorales. Journal of Clinical Microbiology, 2012, 50, 66-75.	3.9	134
204	Environmental prevalence of <i>Cryptococcus neoformans </i> An update. Critical Reviews in Microbiology, 2012, 38, 1-16.	6.1	70
205	A rare case of allergic bronchopulmonary mycosis caused byAlternaria alternata. Medical Mycology, 2012, 50, 890-896.	0.7	29
206	High Prevalence of Azole-Resistant Aspergillus fumigatus in Adults with Cystic Fibrosis Exposed to Itraconazole. Antimicrobial Agents and Chemotherapy, 2012, 56, 869-874.	3.2	164
207	<i>In Vitro</i> Antifungal Activity of Isavuconazole against Madurella mycetomatis. Antimicrobial Agents and Chemotherapy, 2012, 56, 6054-6056.	3.2	45
208	Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. Journal of Antimicrobial Chemotherapy, 2012, 67, 362-366.	3.0	173
209	Isothermal microcalorimetry for antifungal susceptibility testing of Mucorales, Fusarium spp., and Scedosporium spp Diagnostic Microbiology and Infectious Disease, 2012, 73, 330-337.	1.8	19
210	Evidence for genetic differentiation and variable recombination rates among Dutch populations of the opportunistic human pathogenAspergillus fumigatus. Molecular Ecology, 2012, 21, 57-70.	3.9	65
211	Resistance of Asian Cryptococcus neoformans Serotype A Is Confined to Few Microsatellite Genotypes. PLoS ONE, 2012, 7, e32868.	2.5	42
212	Clonal Expansion and Emergence of Environmental Multiple-Triazole-Resistant Aspergillus fumigatus Strains Carrying the TR34/L98H Mutations in the cyp51A Gene in India. PLoS ONE, 2012, 7, e52871.	2.5	180
213	Temperate Climate Niche for (i>Cryptococcus gattii (i>in Northern Europe. Emerging Infectious Diseases, 2012, 18, 172-174.	4.3	62
214	<i>In vitro</i> susceptibility of 188 clinical and environmental isolates of <i>Aspergillus flavus</i> for the new triazole isavuconazole and seven other antifungal drugs. Mycoses, 2011, 54, e583-9.	4.0	46
215	Novel mixed-format real-time PCR assay to detect mutations conferring resistance to triazoles in Aspergillus fumigatus and prevalence of multi-triazole resistance among clinical isolates in the Netherlands. Journal of Antimicrobial Chemotherapy, 2010, 65, 901-905.	3.0	64
216	<i>In Vitro</i> Antifungal Susceptibilities and Amplified Fragment Length Polymorphism Genotyping of a Worldwide Collection of 350 Clinical, Veterinary, and Environmental <i>Cryptococcus gattii</i> Isolates. Antimicrobial Agents and Chemotherapy, 2010, 54, 5139-5145.	3.2	121

#	Article	IF	CITATIONS
217	In Vitro Activity of the New Azole Isavuconazole (BAL4815) Compared with Six Other Antifungal Agents against 162 <i>Cryptococcus neoformans</i> Isolates from Cuba. Antimicrobial Agents and Chemotherapy, 2008, 52, 1580-1582.	3.2	65
218	Candida nivariensis Isolated from an Indonesian Human Immunodeficiency Virus-Infected Patient Suffering from Oropharyngeal Candidiasis. Journal of Clinical Microbiology, 2008, 46, 388-391.	3.9	40